EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec

It is indicated for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumours

Source